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Cell-Mediated Immunity and Its
Application in Toxicology
by Michael 1. Luster,* Jack H. Deant and Gary A.
Boormant
A variety of in vivo and more recently in vitro assays have been described to assess cell
mediated immunity (CMI). Two methods routinely employed in our laboratory to assess CMI
following exposure to chemicals in rodents include delayed hypersensitivity and in vitro
lymphoproliferation. Preliminary studies indicate that depressed delayed hypersensitivity
responses, as performed by a radiometric assay, correlates with altered susceptibility to
infectious agents and tumor cell challenge following exposure to immunotoxic chemicals.
Furthermore, suppression of T-cell lymphoproliferative responses to at least 50% below control
values correlated with depressed delayed hypersensitivity responses and altered host susceptibil-
ity. On the other hand, when suppression of T-cell lymphoproliferative responses are within
50% of control values, delayed hypersensitivity and host susceptibility parameters are not
affected. Assuming adequate technical expertise and accurate data interpretation, CMI assays
of these types can provide a valuable data base for toxicology studies and immunotoxicity
assessment.
Introduction
Reports indicating that exposure to various
environmental pollutants leads to immunological
alterations in laboratory animals and even man has
raised concerns regarding sensitive methodology
for routine assessment of immunotoxicity (1, 2).
One concern in assay battery development is the
use ofappropriate models to examine cell-mediated
immunity (CMI). In recent years, large numbers
of in vivo and more recently in vitro assays have
been developed to assess CMI. To insure accurate
evaluation an in vivo assay, which represents a
holistic approach, and a more defined in vitro
assay, for CMI should be employed. Routinely,
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CMI is assessed in our laboratory by quantitating
in vivo delayed hypersensitivity responses using a
radiometric technique and in vitro lymphopro-
liferative responses following chemical exposure
(3). These techniques and their relationship to
other aspects ofimmunity (i.e., host susceptibility,
humoral immunity and the reticuloendothelial sys-
tem) are examined. Considerations in selecting
appropriate CMI assays include sensitivity, sim-
plicity and extrapolation of dose-response curves
from effect to no-effect levels as well as from
rodent model systems to humans.
Assays for Cell-Mediated
Immunity
CMI is evoked by T-lymphocytes, although mac-
rophages and to a lesser extent polymorphonuclear
leukocytes (PMNs) play an active role in these
reactions (4). CMI is responsible for classical
delayed hypersensitivity reactions (DHRs), rejec-
31Table 1. Assays commonly employed to assess cell mediated
immunity.
In vivo
Delayed hypersensitivity
Skin grafts
Graft vs. host
In vitro
Lymphocyte proliferation
Mitogens
Specific antigens
Mixed lymphocytes
Enumeration of lymphocyte subpopulations
Antigenic determinants on surface membrane
Rosette formation
Complement and Fc receptors
Mediator production by lymphocytes
Migration inhibitory factors
Lymphocytotoxicity
Immune interferon
Assays for polymorphonuclear leukocytes and macrophages
Phagocytosis
Chemotaxis
Cytostasis
Chemiluminescence
tion of transplants, tumor immunity, some auto-
immune diseases and resistance to facultative
intracellular parasites as well as many recurrent
infections. In general, in vivo assays predomi-
nantly measure the effector mechanism of CMI,
while in vitro assays may evaluate cellular compo-
nents. A number of these assays appear to repre-
sent a sensitive and reliable indicator of immuno-
toxicity and will be discussed in some detail.
Table 1 lists some of the more common tech-
niques employed to assess CMI in both humans
and laboratory animals and have been discussed in
detail elsewhere (5). These assays are, in general,
fairly quantitative and capable of detecting either
depression or augmentation. Despite the recent
development ofin vitro techniques, delayed hyper-
sensitivity testing remains the most widely accepted
means of assessing CMI. Other in vivo measures
that have been used to assess CMI in laboratory
animals, include graft vs host and skin graft assays
(2). More recently, a number of in vitro assays
have been developed to assess CMI (5). The
microculture lymphocyte proliferation (LP) assay
utilizes T- and B-cell mitogens (usually plant
lectins or bacterial products), specific antigens or
alloantigens in a one-way mixed leukocyte culture
(MLC) to examine proliferative function in lym-
phocyte populations (6). The assay provides a
relatively simple, reproducible and semiquantative
in vitro correlate for CMI. Various methods have
been used to enumerate lymphocyte subpopula-
tions in peripheral blood of humans and spleens
of mice (7). Enumeration, alone, however, does
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not measure functional capabilities. B-lympho-
cytes possess readilv detectable membrane im-
munoglobulins (mlgs) on the cell surface which
can be detected using fluorescein-conjugated anti-
serum to the Igs. In addition, B-cells possess
receptors for complement and the Fc region of IgG
although other cell subpopulations also possess
these receptors. T-lymphocytes, on the other hand,
can be recognized in some species, excluding
rodents, by spontaneous formation ofrosettes with
sheep erythrocytes (E-rosettes). Additionally, T-
lymphocytes can be identified by distinct antigenic
markers on the surface membrane (e.g., Thy 1).
T-lymphocytes that are antigenically or nonspeci-
fically stimulated, elaborate soluble mediators
referred to as lymphokines. The biological function
ofthese lymphokines are measured by a variety of
in vitro techniques. Migration inhibitory factors
retard the migration of macrophages or PMNs.
Lymphocytoxicity assays quantitate cytotoxic or
cytostatic activity elaborated when sensitized T-cells
are cultured with specific soluble or particulate
antigen. The end point in this type of assay is
quantitation of target cell destruction. Immune
interferon, another type of lymphokine, is active
against a wide range of viruses. Interferon pro-
duction is readily quantitated by determining reduc-
tion of viral plaques in an appropriate tissue
culture system.
There are also a number of in vitro techniques
that specifically assess macrophage and PMN func-
tions. Those assays routinely employed in our
laboratory include chemotaxis, phagocytosis, cyto-
stasis, and chemiluminescence (8). Chemotaxis
reflects the ability ofvarious cells including PMNs,
monocytes and/or lymphocytes to preferentially
migrate to an increasing chemical gradient. These
chemical attractants include components of com-
plement and bacterial products. Phagocytosis of
1Cr-radiolabeled SRBCs is determined on resi-
dent and induced adherent peritoneal cells. Adher-
ent cells are also examined for their ability to
inhibit the growth of various tumor cells in a
microculture growth inhibition assay referred to as
cytostasis and is presumably a measure of activa-
tion.
Delayed Hypersensitivity
Responses
Delayed hypersensitivity responses (DHRs) re-
main the most widely accepted means ofclinical or
experimental assessment of CMI. The reaction is
initiatedbyactively sensitized T-lymphocytes which
respond specifically to the antigen through the
Environmental Health PerspectivesISOTOPIC EAR ASSAY
Chemical Exposure
can occur pre or
post Ag sensitization
- 4I
--4q
( Sacrifice mice and
take ear plugs
1 A Ci/g body wt.
3H-T<R (IP)
Solubilize
and determine
CPM
24 HOURS
0. 03 mg Ag in
r0l intolhe
ear (ID)
DHR Index =
CPM challenged ear
CPM control ear
FIGURE 1. Radiometric ear assay for determining DHRs in chemically exposed mice. Mice are sensitized to an antigen, (e.g., 100 ,ug
keyhole lymphet hemocyanin in Freund's adjuvant). Ten or more days following the last sensitization, mice received 1 ,uCi/g body
weight ofH-TdR; 24 hr later, animals are given 30 ,ug KLH in a volume of 10 ,ul into the pinna ofone ear. The other ear serves as a
control and is injected with saline. After 24 hr the mice are sacrificed, ear plugs taken, solubilized and radioactivity determined.
The data are expressed as an index (CPM Challenged Ear/CPM Control Ear).
release oflymphokines and/or development ofspecific
cytotoxicity without the participation of antibody
(9). Locally it is manifested by cellular infiltration
at the site of antigen administration. In humans,
DHRs are measured by the intradermal adminis-
tration of a panel of antigens to which previous
exposure is likely (10). The response is determined
at the challenge site by measuring the diameter of
erythema and induration at 24 and 48 hr. Anergy
(reduced DHRs) can be interpreted as positive
response to one or less antigens and/or reduced
skin reactions. Depressed DHRs, as most recently
demonstrated by MacLean (11), correlate with
decreased host resistance to infectious agents. In
these studies 178 patients were serially skin tested
following surgery. Ofthe 135 patients in this study
who displayed normal DHRs only 21% developed
sepsis and 2% deaths. In contrast, 65% sepsis and
74% mortality occurred in patients demonstrating
anergy.
Radiometric assays, which offer greater sensi-
tivity than skin tests, are often employed to assess
DHRs in rodents (12, 13). We routinely employ a
modification (3) of a radiometric ear assay origi-
nally described by Lefford (13). This method, as
performed in our laboratory, is depicted in Figure
1. Administration of tritiated thymidine (3H-TdR)
prior to antigenic challenge radiolabels monocyte
precursors in the bone marrow. The response is
presumably represented by mononuclear infiltration
around the reaction site.
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In Table 2 the effects of chemical exposure on
DHRs, as measured by the radiometric ear assay,
are compared to alterations in antibody responses
and host resistance. The panel of host resistance
assays represented in Table 2 are considered
under the influence of CMI and are discussed in
detail elsewhere (14). Although preliminary, the
data in Table 2 indicate that decreased DHRs
correlate with increased host susceptibility to
artificial infection. DHRs did not correlate with
antibody production, since exposure to benzo(a)-
pyrene induced severe depression of antibody
production without concomitant effects on DHRs.
As would be expected, benzo(a)pyrene failed to
alter hose resistance. In mice, we routinely employ
keyhold lymphet hemocyanin (Pacific Biomarine,
Pacific Grove, Calif.) in Freund's adjuvant as an
antigen although a variety of sensitizing antigens
are suitable including extracts of T. spiralis. Good
responses can be obtained in rats sensitized with
complete Freund's adjuvant (e.g., H37Ra; Difco)
and subsequently challenged with purified protein
derivative (PPD; Parke-Davis) (15). While a vari-
ety of antigens can be used to study DHRs, one
needs to select an antigen and sensitization sched-
ule that favors CMI and not antibody synthesis.
Furthermore, consideration must be given to the
time of sensitization in relationship to chemical
exposure. Sensitization prior to chemical exposure
may be considered an assay for memory cell
function, while short-termimmunologicalalterations
33Table 2. Relationship of DHRs, antibody responses and host susceptibility in mice following exposure to various chemicals.
Total dosage, Antibody Host
Species Chemical treatmentsa mg/kg Antigenb DHR index responsesc resistancec
Mice Mpme - KLH 2.93 ± 0.28
DES (pre-sens) 8 KLH 2.94 ± 0.33 44
DES (post-sens) 8 KLH 1.88 ± 0.15d 4 44
Cyclophosphamide 180 KLH 1.54 ± 0.11d 4 44
TCPP 100 KLH 3.13 ±0.26 - -
Benzo(a)pyrene 400 KLH 2.73 ± 0.19 4 -
None - T. spiralis 3.23 ± 0.28 - -
DES (post) 8 T. spiralis 1.67 ± 0.23d 4 44
Rats None PPD 5.64 ± 0.65
TCDD 0.02 PPD 3.17 ± 0.44d d 4
aAll mice were exposed to the various chemicals subehronically at 6-8 weeks ofage. Rats were treated pre/postnatally (viamaternal
exposure) as described previously (15).
bAbbreviations: DES = diethylstilbestrol; TCPP = tris(1,3-dichloropropyl) phosphate; TCDD = 2,3,7,8-tetrachlorodibenzo-p-
dioxin; KLH = keyhole lymphet hemocyanin; T. spiralis = an antigen extract.
"Code: -= no effect; 4 = slight to moderate; 44 = marked effect.
dSignificant decreased from control values (p < 0.01).
may be missed if sensitization is not initiated until
chemical exposure has been completed. Of course,
subchronic 30 to 90 day toxicity studies will tend
to minimize these types of problems.
Lymphoproliferative Responses
Lymphoproliferative (LP) responses are a widely
used correlate of CMI and can be defective in the
absence of lymphopenia. In the microculture LP
assay, general mitogens (e.g., plant lectins, bacte-
rial products), specific antigens or alloantigens
(i.e., mixed lymphocytes) are used to stimulate
selectively the cell proliferation ofsplenic or periph-
eral lymphocytes (6). Proliferation is measured by
3H-TdR incorporation into DNA, represented as
CPM. Unlike specific antigens, mitogens are
polyclonal activators some of which are capable of
tions (see Table 3). In mice, phytohemagglutinin
(PHA) and concanavalin A (Con A) are often used
to activate T-lymphocytes, while lipopolysaccha-
ride (LPS), isolated from gram-negative bacteria,
is used to transform B-lymphocytes (3). Depressed
LP responses occur in humans with inherited
immunodeficiency (primary) diseases as well as
various pathological or physiological conditions,
including malignancies (Hodgkin's disease, lung
cancer), intestinal lymphangiectasia, aging, chronic
lymphatic leukemia, nutritional deprivation and in
severe stress (e.g., post-surgery) (6, 17).
Depressed LP response in experimental animals
with normal numbers of lymphocytes has usually
been interpreted as failure ofcell activation. Recent
studies have indicated that this may occur through
tolerance or suppressor substances produced by
regulatory subpopulations of macrophages and
T-lymphocytes (6, 7). Other factors, however,
Table 3. Lymphocyte activators (mitogens) and their characteristics.a
Source Common examples Cells transformed
Plant extracts Phytohemagglutinin T
Concanavalin A T
Pokeweed mitogen T or B
Bacterial products Lipopolysaccharide (Lipid A) B
Staph. enterotoxin T
Purified protein derivative B
Antibody reagents Anti-immunoglobulin B
CHO antibodies T or B
Miscellaneous chemicals Phorbol ester T
Dextran sulfate B
Metal ions (zinc, mercury, lead, etc.) T or B
aModified from Cunningham et al. (16).
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exposure in mice.
Deviation from control, %
Total dosage, T-Cell B-Cell Antibody Host
Chemical treatmenta mg/kg mitogen mitogen DHR PFC's resistanceb
DES 8 704 291 334 234 44
Cyclophosphamide 180 974 974 474 99 4 4
TCPP 100 254 32 61 13t -/4
Benzo(a)pyrene 400 32 4 54 4 4 75 4
TCDD 0.02 534 184 604 ND 4
PBB 1220 394 354 12t 5T -
o-Phenylphenol 2000 7 4 ll1 13 1 13 t
'TCDD was administered in mice pre/postnatally (via maternal exposure) as described previously (18). PBB was given chronically
(19). All other chemicals were administered as described in Table 2. bCode:. = no effect; 4 = slight to moderate; 44 = marked effect: ND = not done.
should be considered as possibly causing depres-
sion of LP responses. Some of these factors
include: a chemically induced lymphocytotoxicity
as may occur with TCDD (1); redistribution of
lymphocyte subpopulations (i.e., B-, T- or null
cells) as may occur in chronic lymphatic leukemia;
and/or an early maturational defect in lymphocyte
development since mature lymphocytes respond
differently to mitogens than less mature lympho-
cytes. This is not to say that LP assays are not a
reliable predictor of immune alteration but, rath-
er, may prove to be an extremely sensitive indica-
tor of immunotoxicity, if appropriately interpre-
ted.
Table 4 summarizes some recent studies in our
laboratories in which LP responses were compared
to a variety of immunological and host susceptibil-
ity assays in mice following exposure to therapeu-
tic and environmental chemicals. All data reported
were obtained in animals administered dosage
levels that did not induce overt signs of toxicity.
As in Table 2, resistance to the biological agents
used to assess altered host susceptibility in these
studies are considered primarily under the influence
ofCMI and not humoral mediated immunity (HMI).
While preliminary, certain profiles emerged follow-
ing examination ofthese data. As would be expected
a large number of chemicals examined (e.g., o-
phenylphenol) did not effect any host resistance or
immune function assays. Other chemicals, such as
cyclophosphamide, diethylstilbestrol and 2,3,7,8-
TCCD, were clearly immunotoxic, causing greater
than 50% depression of LP responses, suppressed
DHRs, increased host susceptibility and in most
cases depressed antibody PFC responses. In ear-
lier studies these chemicals have been shown to be
selectively toxic to the immune system (1, 8).
Another group of chemicals, such as tris(1,3-
dichloropropyl) phosphate (TCPP) and polybro-
minated biphenyls (PBB), displayed minimal sup-
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pression of LP responses, ranging from 25 to 50%
below control values, without concomitant effects
on other immune parameters or host susceptibili-
ty. Although presently speculative, this immune
proffle may be representative of a general toxicity
rather than a selective effect on the immune
system. Support for this hypothesis has been
provided in collaborative studies with Boorman
(20). In these studies, mice with depressed LP
responses following exposure to TCPP or PBB
also revealed decreased hematopoietic stem cell
proliferation using in vitro spleen and bone mar-
row colony forming assays. Since these chemicals
are biologically active, probably capable ofbinding
to DNA, it would be expected that the more
proliferative cell populations (i.e., stem and lym-
phoid cells) would have a greater predilection to
chemical injury. Benzo(a)pyrene appeared selec-
tively to affect B-lymphocytes while sparing CMI,
although T-cell LP responses were somewhat affect-
ed. This is not a unique phenomenon in immuno-
toxicology, since exposure to heavy metals under
many circumstances induces similar effects (21).
In summary, many assays are available to assess
CMI following chemical exposure. Since, in gener-
al, these assays represent "biological phenomena"
one should employ both in vivo and in vitro assays
for proper assessment. Assay selection should be
based upon sensitivity, simplicity and extrapola-
tion of dose response curves from effect to no-
effect levels as well as from rodent systems to
humans. Preliminary studies reported here, which
should be interpreted with caution, suggest that a
depressed DHR corresponds with increased host
susceptibility. On the other hand, while marked
suppression of T-cell LP responses correlates with
suppressed DHRs, less severe depression does not
correlate with other immune or host resistance
parameters, but rather may be an early indicator
of general toxicity.
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